Clinical trials: Psychotic Episode
Psychosis
Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine
This study will examine the differential relationships between antipsychotic efficacy and changes in dopaminergic and glutamatergic brain metabolism in lumateperone and risperidone treated early psychosis patients.
- Trial name
- Lumafep (NCT05890768)
- Testing
- Lumateperone, Risperidone
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia
Early Medication Discontinuation and Long-term Clinical Outcome in FEP
The study aims to examine the relationship between early maintenance therapy decisions in first episode psychosis, and the subsequent long-term clinical outcome at 9-10 years by comparing a group of patients who were randomized…
- Trial name
- FEP (NCT01926340)
- Where
- Hong Kong
- Volunteers
- 178 people
- Sponsor
- Professor Eric Y.H. Chen
Schizophrenia
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia
This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic…
- Trial name
- NCT05168007
- Testing
- WID-RGC20(Cariprazine) 3mg/day, WID-RGC20(Cariprazine) 6mg/day
- Where
- South Korea
- Volunteers
- 342 people
- Sponsor
- Whanin Pharmaceutical Company
Schizophrenia, Bipolar Disorder
Integrated Care Including Assertive Community Treatment in Early Psychosis
Improvement of clinical long-term outcome through the implementation of early detection and intervention within a specialized network of integrated care (ACT and hometreatment) for adolescents and young adults with a first…
- Trial name
- ICEP (NCT02037581)
- Testing
- Early detection and Integrated Care, Standard Care
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia
Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies
Researchers propose in this project to evaluate predictive factors of non response. It is defined by the lack of symptomatic remission at month 3, for patients presenting a first episode of psychosis.
- Trial name
- PEPsy (NCT02670447)
- Testing
- MRI
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Schizophrenia
cTBS on First-episode Drug Naive Patients With Schizophrenia
cTBS is a promising novel intervention, which have strong potentials on moderating disease syndrome, suck as verbal hallucination, and cognitive deficits in schizophrenia, as it has been proved for the treatment of depression.
- Trial name
- NCT05086133
- Testing
- transcranial magnetic stimulation
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Central South University
Schizophrenia, Psychotic Disorders
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings…
- Trial name
- PSYDEV (NCT04370730)
- Testing
- clinical, neuroimaging and DNA assessments
- Where
- 6 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia (Recent-onset)
Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.
- Trial name
- NCT01451736
- Testing
- paliperidone palmitate, risperidone
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
First Episode Psychosis
Early Intervention Psychosis Communication and Engagement Trial
This study will examine whether or not the use of digital communication methods (text messages and emails) improves patient engagement with Early Intervention Psychosis (EIP) Services, compared to standard communication methods…
- Trial name
- NCT03196128
- Testing
- Digital communication, Non digital
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- South London and Maudsley NHS Foundation Trust
Schizophrenia, Schizophrenia Relapse
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP (NCT02220504)
- Testing
- Antipsychotic treatment discontinuation, Maintenance antipsychotic treatment
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Bipolar Disorder, Schizophrenia
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
The basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence.
- Trial name
- SEQUEL (NCT00533260)
- Where
- 35 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia
This study attempts to observe the efficacy (response time) and safety of the second-generation antipsychotic agent-quetiapine versus the first-generation antipsychotic agent-haloperidol, in treating acute schizophrenia episode…
- Trial name
- NCT00631722
- Testing
- Quatiapine Fumarate, Haloperidol
- Volunteers
- 80 people
- Sponsor
- Peking University
Schizophrenia
Cost-effectiveness of Interventions in First-episode Psychosis
Schizophrenia has very significant economic consequences. Costs fall on many different parts of society, especially on individuals with schizophrenia and their families.
- Trial name
- PAFIPEC (NCT02916303)
- Where
- Spain
- Volunteers
- 490 people
- Sponsor
- Fundación Marques de Valdecilla
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment, Active Control
Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)
Primary study: This study is a single-site, double-blind, randomized, controlled clinical trial to compare an evidence-based structured program of 30-35 hours of on-line cognitive and social cognitive training exercises performed…
- Conditions
- Treatment, Active Control, Schizophrenia, Psychosis
- Trial name
- NCT02782442
- Testing
- Structured Cognitive Training & PRIME, Computer Games Control & PRIME
- Where
- 2 sites in United States
- Volunteers
- 109 people
- Sponsor
- University of Minnesota
Psychosis
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2.
- Trial name
- NCT00449397
- Testing
- Quetiapine Fumarate
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Schizophrenia, Major Depressive Disorder (MDD)
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive…
- Conditions
- Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
- Trial name
- NCT07549581
- Testing
- SEP-380135
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.